

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Christine L. Brakel, et al.

Serial No.: 446,235

Filing Date: December 1989

Group Art Unit: 183

Examiner: Gary Kunz

Title: Modified Nucleotide Composites

Honorable Commissioner of Patents and Trademarks
Washington, D.C. 20231

RECEIVED GROUP 180

JUN 07 1991

Sir:

Transmitted herewith is an amendment in the above-identified patent application.

The fee has been calculated as shown below:

P 30065	06/12/91	07446235	05-1135	030	102	60.00CH
	06/12/91	07446235	05-1135	030	103	60.00CH
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDITIONAL FEE
Total	54	Minus	54	= 0	x 12	\$ 0
Indep	7	Minus	7	= 0	x 36	\$ 0
() First Presentation of Multiple Dependent Claims					+ 120	\$ 0
TOTAL ADDITIONAL FEE -----						\$ 0


() Charge Deposit Account No. 05-1135 in the amount of \$_____.

() A check in the amount of \$_____ is attached.

(x) The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 05-1135: any filing fees under 37 CFR 1.16 for the presentation of extra claims and any patent application processing fees under 37 CFR 1.17.


Copies are being provided in triplicate.

Date: May 31, 1991


Ronald C. Fedus
Attorney for Applicants
Registration No. 32,567

ENZO THERAPEUTICS, INC.
c/o Enzo Biochem, Inc.
60 Executive Boulevard
Farmingdale, NY 11735
(212) 924-5409 or 924-9578

Case No.: **Enz-47**

EXPRESS MAIL CERTIFICATE	
"Express Mail" Label No.	FB 287212431
Deposit Date	May 31, 1991
I hereby certify that this paper and the attachments herein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington DC 20231	
 Ronald C. Fedus Reg. No. 32,567	<u>MAY 31, 1991</u> Date